Introduction
The trough:peak ratio of drug effect has become established as a convenient measure of the duration of action of a drug and the suitability of a given dose interval. Although the concept is valid for any drug class and has been described for bronchodilators, 1, 2 it has found particular application for antihypertensive drugs. The ratio is used as an informal yardstick for regulatory purposes by the US Food and Drug Administration in new drug applications involving once-daily dosing for such drugs. 3 Essentially, the ratio encapsulates the idea that once-daily administration of an antihypertensive drug is legitimate if the effect on blood pressure (BP) is evident throughout the 24-h dose interval. For such a drug the trough (pre-dose) effect on BP will be measurable and the ratio of trough to peak effects is greater than zero. The FDA guidelines suggest that the ratio should be in the range 0.5-0.66, and the maximum possible value (setting problems of measurement aside) is one because by definition trough effect cannot exceed peak. For the concept to have validity in the treatment of a chronic condition such as hypertension, the ratio should be defined during longterm treatment.
Through the trough:peak ratio has the apparent merit of simplicity, several issues about its validity and application are unresolved. Amongst these are: (a) how the ratio is determined; (b) the optimum value and reproducibility of the ratio, and whether it is sensitive to drug class or indication; (c) where the ratio stands in relation to conventional pharmacokinetic concepts, given that it is derived from effect-time data; (d) since the ratio is sensitive to dose, the relationship between the ratio and the methods used to determine dose (or more accurately, tablet sizes); and (e) the generalisability of the measurement when derived from small numbers of highly selected patients studied in a highly controlled environment.
In this review I discuss these issues and question some statements made in the literature about the trough:peak ratio.
Problems with measurement

Placebo effects
In spite of the conceptual simplicity of the trough: peak ratio, accurate measurement is a matter of some controversy. Both 'peak' and 'trough' have to be defined and measured rigorously, and this poses both practical and theoretical problems. Trough is defined in relation to the next dose, and the major uncertainty is the extent to which the taking of medicines differs in trials and daily life, since systematic differences in this respect or in between-day variation in the timing of the dose affects the ratio. Peak is less easily measured. The point of maximum effect (T max ) varies between patients, especially for drugs with a relatively long duration of action, and continuous surveillance of BP is required for identification. In addition, background diurnal trends in BP mean that the maximum daily BP during treatment does not necessarily correspond to the peak effect. Hence accurate measurement of peak drug effect and T max requires diurnal BP variation and placebo effects to be taken into account. In other words, the best means of defining the trough:peak ratio is by prospective placebo-controlled studies using ambulatory monitoring techniques. Elliott and Meredith have demonstrated 4, 5 how ignoring placebo effects can give erroneous measurements of both the extent and timing of the peak effect and of the trough:peak ratio.
The most rigorous study design is the comparison of BP before and after active treatment compared with corresponding measurements before and after placebo. Such a study is demanding of patient and investigator alike, and can give misleading results because placebo treatment has little 6 if any 7, 8 real effect on BP. Differences in the baseline and placebo studies are more likely to be due to random BP variation 9 or to period effects related to reduction in alerting reactions or regression to the mean. The final effect of the drug on BP at any time point (or time period over which ambulatory data are averaged) in a two-phase placebo-controlled study is obtained from four measurements by:
[ 10 Since random BP variation is relatively more important when the real drug effect is small, drugs with low trough:peak ratios or a small drug effect at trough are particularly liable to be influenced by BP variability. 11 Hence the overall rigour of the controlled study may be counterbalanced by an increase in variance of the final data. This can lead to an imprecise measure of peak and trough effects, and the imprecision is compounded by expressing them as a ratio. 12 This source of error has been well studied [9] [10] [11] and may be as high as 80-90%, 12 but nevertheless most authors have presented trough:peak ratio data as a single mean figure without any measure of reproducibility or range, and the FDA guidelines do not refer to reproducibility of trough:peak data.
An effect of random BP variation on the estimate of trough:peak ratio has been confirmed in practice 9 and is demonstrated by an analysis of data from the study by McCarron 13 ( Figure 1 ). In this study of ramipril given once daily at a dose of 10 mg, the graph of BP against time uncorrected for placebo indicates that the drug has a significant antihypertensive action throughout the dose interval. The effect of ramipril in relation to baseline shows a peak effect on BP at 4 -6 h followed by a progressively decreasing antihypertensive effect to the trough value, as expected. The calculated trough: peak ratio is 0.45. However, after subtraction of the placebo curve, the net effect is highly variable throughout the day, the peak appears at 7-9 h, and the trough:peak ratio is higher (0.57). Thus application of a method which is intended to optimise measurement of the ratio produces a time course of drug action which is intrinsically unlikely and appears unreliable. The initial absolute 24-h plot comparing treated BP with baseline values but without correction for placebo has intuitive appeal, and in this case appears to be the more valid measure of the overall time course of drug action and trough: peak ratio.
Responders and non-responders
Hypertensive patients may be classed as 'responders' or 'non-responders' to antihypertensive (his table II) and are plotted as the mean of measurements obtained over 3-h intervals in 100 patients with mild to moderate hypertension after 4 weeks of treatment using a non-invasive ambulatory device (Spacelabs Inc).Top panel, SBP before (᭺) and after (b) ramipril treatment; middle panel, change in SBP at each time period compared to baseline measurements for both placebo (̅) and active treatment (̆); bottom panel, change in SBP after treatment with ramipril corrected for the placebo changes shown in the middle panel. For the uncorrected data, T max is at 4 -6 h (plotted at 6 h) and the trough:peak ratio is 0.45. For the placebocorrected data, T max is at 7-9 h and the trough:peak ratio is 0.57. drugs according to whether BP is decreased from baseline by a defined amount (say 10 mm Hg) or reaches a pre-defined limit (say 90 mm Hg). Using these definitions, approximately 60-70% of patients may be classed as responders to individual drugs. The question arises whether the trough:peak ratio should be measured in all patients or only in those who respond; and conversely a drug which is reported to have a ratio of unity must have been studied only in responders. Since the ratio is usually given as a single value and has the misleading appearance of a population mean parameter value, there is an implication that it should be measured in a representative randomly selected patient population and reported as the population mean value. The same consideration suggests that peak effects should be measured at a standard rather than individual T max . If this reporting method is used, the value of the ratio and its variance will reflect the natural variation in drug responses, including nonresponse. On the other hand, if the ratio is obtained only in patients who respond, then it is more likely to be clinically meaningful. Though it is difficult to predict whether an individual patient will be a responder or non-responder, in practice a drug is likely to be discontinued in patients who fail to respond. Thus patients taking a given drug will tend to be responders, and the ratio in this sub-population is the one of interest.
If non-and partial responders are included, what is the likely consequence? By definition, peak effect in a non-responder is zero, as is trough, excluding random effects. The ratio is indeterminate in that individual, or could be taken to be zero. The population ratio value will then underestimate the true value in responders, and the variance will be greater. The situation in a partial responder is potentially more complex. If errors in measurement or random effects are excluded, it is similar to the effect of using a lower dose in a responder, ie, a measurable but sub-optimal peak effect is associated with a smaller or zero effect at trough. Hence the ratio may be the same as in responders if peak and trough effects decline proportionately, or it may be low or zero. However, when the peak effect is small and a non-zero value is obtained for trough effect because of systematic errors in measurement or random variation of BP, spuriously high values for trough:peak ratio approaching or even greater than unity may be obtained. Similarly, negative values for the ratio can arise if the placebo effect is by chance greater than the treatment effect. 12 Hence, the likely effect of including non-responders is to underestimate the trough:peak ratio, but paradoxical and spurious over-estimation is possible if the methodology of measurement is not strictly controlled.
Setting the last effect aside, the likely overall effect of including non-responders in the measurement is to underestimate the trough:peak ratio, possibly leading to avoidance of a drug whose therapeutic properties are actually acceptable. For these reasons, the greatest benefit with the available drugs is obtained if trough:peak ratio is calculated using data from responders only. This conclusion agrees with that of other authors.
8,9
Relation of trough:peak ratio to pharmacokinetics
Since the trough:peak ratio is ultimately derived from the time-course of drug effects, it is relevant to explore its relationship with classical pharmacokinetics and pharmacodynamics. One possible criticism of the ratio is that by taking effects at only two time points for simplicity, important kinetic information is ignored. It is often implied 5, 14 and occasionally stated 15 that the trough:peak ratio for antihypertensive drugs should approach unity, and there is indeed an immediate appeal in the idea that a drug should exert its effect in an undiminished manner throughout the day. However, for some drugs a high trough:peak ratio is inconsistent with pharmacokinetic principles. A high ratio also implies that continuous unmodified control of BP throughout a 24-h dose interval is safe, but this is currently unproven.
Relationship to dose interval
Pharmacokinetic principles state that the dose interval for a given drug is fixed by the elimination kinetics. If the dose and dose interval are determined by kinetic analysis, then the trough:peak ratio of BP lowering will be fixed according to the corresponding pharmacodynamic properties. In chronic treatment, the dose interval should be of sufficient duration to allow elimination of the previous dose at the required steady-state of plasma drug concentration. This principle applies to drugs for which the total available dose is within the body and the only process occurring is elimination. For a drug whose kinetics approximate to a single-compartment model, a reasonable dose interval is determined after the dose giving the desired effect at peak is defined, by the elimination kinetics measured as plasma half-life (t . ). A dose interval of at least 2.5 × t . is required 16 to avoid compromising the capacity to eliminate the previous dose ('accumulation'). The relationship between the tendency to accumulation and dose interval is not linear, and the tendency becomes disproportionately more marked as the dose interval decreases. 16 If the dose interval is shorter than 2.5 × t . , a steady-state will be reached at a higher concentration. The risk in such a situation is of drug toxicity. High concentrations may be avoided by giving a lower dose, but this approach may have implications for efficacy. In summary, there is a relationship between dose, elimination kinetics and dose interval which imposes certain restrictions on the frequency with which a drug should be administered. These restrictions may be suspended at the expense of therapeutic efficiency.
If we consider a drug which has dynamic effects that are directly related to the plasma concentration, it is immediately clear that a dose interval of 2.5 × t . and a high trough:peak ratio cannot be present simultaneously. If the 2.5 × t . rule is complied with and 24-h dosing is appropriate, the drug elimination t . can be no greater than about 10-12 h. In this case the trough:peak ratio must lie between 12.5 and 25% since it is related to effects on BP that decline in proportion to the plasma concentration. Conversely, if a drug is absorbed, has peak effect 4 h after administration and a measured 24-h trough:peak ratio of 0.8 then the implied t . is 62 h for which the appropriate dose interval on kinetic grounds would be 6.5 days. Hence, when an antihypertensive drug with an elimination t . greater than about 12 h and exhibiting concentration-dependent effects on BP is given once daily, a high trough:peak ratio may be obtained but the principles which determine dose interval may have been violated and accumulation is a possibility. In general, a high trough:peak ratio can imply that a drug is being given too frequently or that the dose is excessive. If so, steady-state drug concentrations may be higher than necessary and the risk of side effects is greater. Thus a high trough:peak ratio is not necessarily desirable, since it may be simply a proxy for either excessive dosing or inappropriately short dose intervals.
This argument applies only to drugs which exert a concentration-dependent action, such as the vasodilator effect of dihydropyridine calcium channel blockers. Some members of this class have very long half-lives (Ͼ24 h) and have high daily trough:peak ratios. The above logic suggests that this combination of properties could arise because either unit tablet sizes are too high or the dose interval is unduly short. It is of interest that amlodipine, which has an intrinsically long t . (c. 40-50 h) and high 24 h trough-peak ratio, displays an antihypertensive action for at least 48 h. 17 For this drug, the conflicting kinetic and dynamic properties would be theoretically reconciled by a 48-h (or longer) dose interval (or by reduction in the unit tablet size). This suggestion requires to be tested by a formal clinical trial. Recent trial evidence 18 suggests that amlodipine is safe in patients with heart failure, in spite of the above considerations.
What is the situation for other drugs? For slow release formulations, perhaps best exemplified by the GITS formulation of nifedipine, 19 additional drug is made available for absorption during the dose interval at a rate which replaces drug lost to the body by clearance. Hence plasma drug concentration is maintained at a value that produces the desired effect on BP even though the clearance of the drug is rapid (ie, it has a short plasma t . ). In this situation the trough:peak ratio can be manipulated by the manufacturer simply by varying the size of the drug pool available within the reservoir, and is independent of elimination kinetics. If a higher ratio is required, the reservoir (ie, the dose) may be increased, and vice versa for lower ratios. Thus for slow release preparations the main issue for the manufacturer is knowledge of the optimum value of the trough:peak ratio and the dose of the drug in the reservoir formulation which gives that value.
Some drugs exert an effect on BP that is not directly dependent on plasma drug concentrations. For example, angiotensin-converting enzyme (ACE) inhibitors have tissue actions as well as direct vascular effects, act by competitive inhibition of an enzyme and obey non-linear kinetics, and affect more than one BP-modulating system (notably the renin-angiotensin and kallikrein-kinin systems).
These drugs have a theoretical maximum effect on BP corresponding to the concentration at which effective 100% inhibition of the enzyme is achieved in target tissues. If this occurs at some time point after administration (T max ) the effect will be maintained until the plasma and tissue drug concentrations fall below this concentration. The time course of BP depends on various factors such as the Michaelis-Menten relationship between the drug and the rate of the reactions catalysed by ACE in plasma and tissues, ie, by the V max and K m of each reaction, the concentration and K i of the drug, and the concentrations of the various substrates (angiotensin I, bradykinin etc). For this class of drugs the antihypertensive effect can persist after plasma drug concentrations have declined, and they may have a high trough:peak ratio but nevertheless satisfy the classical determination of dose interval based on timed measurements of plasma drug concentrations.
The principles described in the previous paragraphs are depicted in Figure 2 . In summary, for drugs which exhibit marked dynamic concentration dependence and are subject to rapid absorption, a high trough:peak ratio indicates that the dose is too high or the dose interval is too short. For such drugs, a high trough:peak ratio risks relative overdose and increased incidence of side-effects. On the other hand, for slow-release preparations or for agents whose central compartment drug concentrations are not directly related to BP lowering, a high trough: peak ratio may be desirable. In other words, a nonselective policy which aims for a high trough:peak ratio for all antihypertensive drugs is misplaced.
The effect of dose
As an illustration of the relationship between trough:peak ratio and dose, and the potential consequences of varying the ratio of manipulating dose, consider the history of the ACE inhibitor, captopril. Captopril has its maximum effect on BP at a concentration giving complete inhibition of converting enzyme. This occurs with a dose of about 25 mg in an adult. However, captopril has a relatively short elimination t . and its effect on plasma ACE at this dose is short-lived. Trough:peak ratios less than 0.5 have been documented even with twice-daily dosing, 20, 21 though other studies have suggested that captopril at a dose of 50 mg once daily may control BP over 24 h in spite of its rapid elimination. 22 The explanation for this apparent inconsistency is not clear. One way of extending the duration of action is to give high doses which produce supra-maximal concentrations and thus ensure prolonged ACE inhibition. This was done deliberately at an early stage of captopril's development, and routine daily doses of 500 mg or more were described. 23 Effectively (but not explicitly, because this was before the term 'trough:peak ratio' was coined) the ratio 'improved' but at the expense of high body captopril concentrations. Serious renal, skin and bone marrow toxicity emerged, and the doses were reduced to current values.
The experience with captopril illustrates several important points. First, the trough:peak ratio of an antihypertensive drug for a given dose interval is related to dose, and the ratio is only valid when the dose to which it relates is specified. Unlike measures such as volume of distribution and clearance, the trough:peak ratio is not an intrinsic pharmacokinetic parameter of a drug, though it is often presented as such. Second, and by way of corollary, the method used to determine dose (or more practically, unit tablet size) requires examination, since if this process deliberately or inadvertently results in unit doses that are larger than necessary for the desired therapeutic effect then the resulting measurement of trough:peak ratio will also be high. Lastly, the use of high doses to extend the duration of drug action and increase the trough:peak ratio to apparently more favourable values carries an increased risk of drug side effects. This is especially hazardous when the process is driven by non-scientific factors such as the marketing advantages of once-daily dosing.
With the advent of the trough:peak ratio as a regulatory tool, it is possible that manufacturers will seek to conform with the guidelines for a ratio within a specified range by conducting studies to discover the dose which maximises the ratio. This cyclical logic would be a perverse and undesirable outcome. In short, the suggestion that trough:peak ratio should be within a certain range is potentially hazardous and misleading unless the method used to determine doses are also regulated.
Potential for harm using drugs with a high trough:peak ratio
Excessive effect on BP
Most patients take once-daily antihypertensive medication in the morning. If the drug has a high trough:peak ratio, the peak effect is (by definition) carried through unabated to the evening, when BP normally tends to fall during sleep. Since trough: peak ratio is defined according to absolute and not relative reduction in BP, the proportionate effect on BP by a drug with a high trough:peak ratio taken in the morning is greater during sleep than during the day, and the tendency for BP to fall at night (which is preserved in many hypertensive patients) will be augmented by the full antihypertensive potential of the drug. Does such a treatment effect on BP necessarily confer benefit?
It is generally assumed that a significant antihypertensive effect during sleep is beneficial because total 24-h BP correlates best with cardiovascular risk [24] [25] [26] and because patients whose BP does not fall at night ('non-dippers') show strong associations with markers of cardiovascular disease. 25, 27, 28 The changes in BP probably reflect corresponding changes in peripheral resistance. 29 These data suggest that a hypertensive drug which produces a fall in BP during sleep is likely to confer a treatment benefit, at least in 'non-dippers', but the hypothesis is not strictly logical. As clinical trials of antihypertensive drug treatment have shown, reversal of a risk factor does not necessarily reverse the associated risk. Also, the correlation between night-time BP and cardiovascular events has been disputed, 30 and the presumed advantage of high trough:peak ratio drugs in this context has not been demonstrated in any prospective clinical trials.
Though there is a theoretical basis for assuming a treatment benefit in hypertensive patients whose BP does not fall during sleep ('non-dippers'), an assumption of any benefit in 'dippers' is speculative. Firstly, these patients are at lesser risk, and so the potential gain from treatment is less. Furthermore, full expression of the antihypertensive action of a drug in patients whose BP naturally falls during sleep may be hazardous if a frankly hypotensive BP is reached. Stroke and myocardial ischaemic events are frequent during sleep, possibly associated with and causally related to low BP, and an additional antihypertensive action may exaggerate the problem. Hence two opposing clinical outcomes, neither of which has support from clinical trials, are possible when high ratio drugs are used in treatment. Three patient groups are of particular concern: hypertensive patients in whom the tendency of BP to fall at night is maintained, patients with impaired postural reflexes due to aging or drug therapy, and patients with labile BP (pseudohypertension) in whom antihypertensive drugs are not indicated but who are in fact receiving drug treatment. Any BPlowering effect of the drug while asleep may be exaggerated if the patient rises at night.
There are no prospective or retrospective studies designed to determine whether cardiovascular outcome is altered by using drugs with a high trough: peak ratio, or which of the two opposing effects mentioned above holds true. Hence the belief that drugs with a high trough:peak ratio are preferable seems premature. Interpretation of 24-h BP data remains matter of controversy and any conclusions drawn from available data should be regarded as provisional. In this situation it seems proper to express caution and to draw attention to the possibility of harm using drugs whose full antihypertensive action is maintained during a period of the day when BP tends to fall.
It is of interest that the effect of antihypertensive drugs on BP variability is not correlated with the trough:peak ratio, 9 but various common antihypertensive drugs have differential actions on BP variability. 31 It remains to be seen whether the action on BP per se or on BP variability is the more important determinant of cardiovascular risk. If variability is important, the relevance of the ratio will need to be reconsidered.
Increased risk of side effects
Since a high trough:peak ratio may arise because the dose is too high or the dose interval is too short in relation to elimination kinetics, high ratio drugs may place the patient at risk of adverse reactions, especially those that are dose-related and with drugs with high concentration dependency. This is opposite to the usual claim, that drugs with rapid clearance and low 24 h trough:peak ratios are associated with increased incidence of side-effects due to the marked changes in drug concentrations during the dose interval. However, the two statements are not necessarily mutually exclusive, since they refer to relatively long and short time periods respectively. In addition, it is necessary to distinguish between known acute and perhaps trivial side effects (headache, etc) and clinically significant long-term drug-related events such as myocardial infarction or premature death.
Recently, controversial evidence from meta-analyses that dihydropyridine calcium channel blockers have serious coronary side effects at high dose has been published. 32, 33 These findings have been criticised on methodological grounds, and the studies in the meta-analyses antedated the availability of very long-acting dihydropyridines or effective slowrelease formulations. The common side effects of dihydropyridines are related both to dose and the kinetic properties of individual drugs, such that formulations giving high 24-h trough:peak ratios have fewer immediate side effects such as flushing and headache. 34 Absence of short-term side effects by these agents may not translate to freedom from longterm adverse reactions affecting mortality, such as coronary events. If the reported association actually exists and is a class effect, formulations with high trough:peak ratios may not be safer than their predecessors in spite of their improved short term acceptability. As argued above, a high trough:peak ratio for drugs in this class may imply relative overdose, and the doses of some dihydropyridines may need to be decreased or the dosage interval increased. These comments do not necessarily apply to slow-release preparations but the safety of such formulations should be demonstrated.
All antihypertensive drugs can cause hypotension as an adverse reaction in susceptible patients. This is recognised as being more serious when the offending drug has a prolonged duration of action or high trough:peak ratio, since the adverse effect takes longer to wear off. The property is a further reason to be skeptical that a high trough:peak ratio is necessarily good. Poorly compliant patients who tend to skip doses may obtain greater protection against high BP using agents with high trough:peak ratio, but this is an intrinsically weak argument in support of high ratio drugs since it could have the effect of placing compliant patients at risk in order to secure a theoretical advantage in those who are not compliant.
The optimum trough:peak ratio
Theoretical analyses have concentrated on how trough:peak ratio should be measured, not what the optimal value should be. It has been stated that the ratio should be as high as possible and should ideally be unity (100%), but this claim has little if any theoretical basis. If the optimum trough:peak ratio is unity, the suggested informal FDA guidelines of 0.5-0.66 appear at face value to allow the registration of once-daily formulations that fail to meet the purportedly ideal ratio.
It appears that the determination of the ratios comprising the FDA guidelines was arbitrary, but based on intuitive insights into values that would avoid side effects, provide for some effect on BP at the end of the dose interval, and offer a degree of protection against inadvertent omission of dose. Definition of the range 0.5-0.66 for the trough:peak ratio is reported as having been given as a casual answer to an informal question put verbally to a senior official of the FDA. 35 No theoretical justification has been published, and there is no evidence to demonstrate that drugs with this range of trough: peak ratios have advantages over drugs with greater or lesser ratios with respect to primary cardiovascular end-points. No range of trough:peak ratios has theoretical support, and the considerations raised here suggest that different ranges may be required for different types of agent and possibly for different indications. On the other hand, the intuitive ideas on which the range of ratio specified in FDA guidelines appear reasonable, and avoid the pitfall of favouring very high trough:peak ratios on the unsubstantiated basis that they are somehow intrinsically desirable.
Summary and conclusion
The trough:peak ratio is a conceptually simple measure of the duration of antihypertensive drug action, but it is difficult to measure and may be invalid for certain drugs. It lacks a sound theoretical basis and its optimum value is not known. Nevertheless the ratio is arbitrarily applied in the process by which an antihypertensive drug becomes registered for once-daily dosing in the USA. It is not logical to argue that the ratio should necessarily be high (around unity), and high values for some drugs may imply a dosing schedule or pharmacokinetic situation that is undesirable and which may be associated with drug accumulation, adverse drug reactions, and possible excessive antihypertensive effects. The notion of the trough:peak ratio and its role in the process of drug evaluation and marketing needs to be critically reconsidered.
